Riskpilot← Back to searchSign inGet full accessSinfonia Biotherapeutics AB
ABBankruptOrg 5591329593StockholmResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20170 employees
Revenue 2022
SEK 61K
+144% vs 2021
EBITDA margin
-34244.3%
-156% vs 2021
Equity ratio
-110.6%
Financial strength
Net profit 2022
SEK -20,9M
-157% vs 2021
| Revenue | SEK 61K | +144% |
| EBITDA | SEK -20,9M | -156% |
| Net profit | SEK -20,9M | -157% |
| Total assets | SEK 1,9M | -92% |
| Equity | SEK -2,2M | -111% |
| Employees | 0 | — |
Legal name
Sinfonia Biotherapeutics AB
Org number
5591329593
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8 november 2017
Share capital
SEK 65 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska direkt och eller indirekt, bedriva forskning, utveckling, tillverkning och försäljning av rekombinanta peptider och proteiner samt cell- och genbaserade terapier för behandling av smärta, hörselsjukdomar och neuroligiska sjukdomar.
Address
Stockholm
Email
urban.hjelm@walthon.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 68 | 529 | 25 | 61 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −23 | −5 198 | −3 030 | −8 151 | −20 889 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −22 |
| EBIT | −23 | −5 198 | −3 030 | −8 151 | −20 911 |
| Net financials | — | — | — | — | −1 |
| Profit before tax | −23 | −5 198 | −3 030 | −8 152 | −20 912 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −23 | −5 198 | −3 030 | −8 152 | −20 912 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 2 613 | 6 683 | 4 393 | 25 967 | 1 948 |
| Equity | 27 | 4 847 | 3 817 | 18 758 | −2 155 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 586 | 1 837 | 576 | 7 210 | 4 103 |
| Total debt | 2 586 | 1 837 | 576 | 7 210 | 4 103 |
EBITDA margin
-34244.3%
This company
15.8%
Market median
-216836% vs market
20182022
Equity ratio
-110.6%
This company
38.2%
Market median
-390% vs market
20182022
Return on equity
-2091200000.0%
This company
18.4%
Market median
-11365217491% vs market
20182022
Net profit margin
-34282.0%
This company
8.1%
Market median
-423335% vs market
20182022
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20182022
Debt / equity
1.90×
This company
0.62×
Market median
-206% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-11-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
UH Liquidator | Liquidator | 2024 |
| Former (3) | ||
JG Chief Executive Officer | Chief Executive Officer | 2021 – 2024 |
NP Chief Auditor | Chief Auditor | 2021 – 2024 |
LU Chief Executive Officer | Chief Executive Officer | 2021 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (4) | ||
| Board of Directors | 2022 – 2024 | |
| Chairman | 2021 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sinfonia Biotherapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Gunnarsson Lundkvist | Chief Executive Officer | 0 companies |
| Nils Per Micael Schultze | Chief Auditor | 0 companies |
| Lars Ulrik Wahlberg | Chief Executive Officer | 0 companies |
| Urban Hjelm | Liquidator | 0 companies |
| Per Ingemar Arvidsson | Board of Directors | 0 companies |
| Thomas Pollare | Chairman | 0 companies |
| Karl-Olof Larsson | Board of Directors | 0 companies |
| Sven Johan Bertil Edvin Sandin | Board of Directors | 0 companies |